Global Information
회사소개 | 문의 | 위시리스트

신경내분비종양(NET) : 역학 예측(2028년)

Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2028

리서치사 DelveInsight Business Research LLP
발행일 2019년 09월 상품 코드 650458
페이지 정보 영문 100 Pages
가격
US $ 3,250 ₩ 3,922,000 PDF by E-mail (Single User License)
US $ 6,500 ₩ 7,845,000 PDF by E-mail (Site License)
US $ 9,750 ₩ 11,768,000 PDF by E-mail (Global License)


신경내분비종양(NET) : 역학 예측(2028년) Neuroendocrine Tumors (NETs) - Epidemiology Forecast to 2028
발행일 : 2019년 09월 페이지 정보 : 영문 100 Pages

주요 7개국(미국, 영국, 독일, 프랑스, 스페인, 이탈리아, 일본)의 신경내분비종양(NET : Neuroendocrine Tumors) 유병 수는 2017년에 45만 3,191명으로 추산되고 있습니다.

주요 7개국(미국, 영국, 독일, 프랑스, 스페인, 이탈리아, 일본)의 신경내분비종양(NET) 역학에 대해 조사했으며, 질환의 개요, 국가별 유병 수 및 이환수 추이와 예측, 치료 알고리즘, 미충족 요구 등에 대해 정리하여 전해드립니다.

목차

제1장 주요 인사이트

제2장 신경내분비종양(NET) 역학 개요

  • 신경내분비종양(NET)의 분포 상황(실적)
  • 신경내분비종양(NET)의 분포 상황(예측)

제3장 질환 배경과 개요 : 신경내분비종양(NET)

  • 서론
  • 신경내분비종양(NET)의 분류
  • 원인
  • 위험인자
  • 증상
  • 병태생리
  • 진단

제4장 역학과 환자 인구

  • 주요 조사 결과
  • 주요 7개국의 총 유병 수
  • 주요 7개국의 총 이환 수

제5장 신경내분비종양(NET)의 역학 : 국가별

  • 미국
    • 총 유병 수
    • 총 이환 수
    • 진단 유병 수
    • 유병 수 : 증상별
    • 유병 수 : 악성 종양별
    • 유병 수 : 부위별
    • 유병 수 : 등급별
    • 유병 수 : 병기별
  • 유럽 5개국
    • 독일
      • 총 유병 수
      • 총 이환 수
      • 진단 유병 수
      • 유병 수 : 증상별
      • 유병 수 : 악성 종양별
      • 유병 수 : 부위별
      • 유병 수 : 등급별
      • 유병 수 : 병기별
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본

제6장 치료 알고리즘

제7장 미충족 요구

제8장 부록

  • 조사 방법

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

KSA 19.09.09

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Secondary causes of nephrotic syndrome
  • Table 2: Systems of nomenclature for NETs
  • Table 3: Grading systems for NETs
  • Table 4: Total Prevalent Population of NETs in the 7MM (2017-2028)
  • Table 5: Total Incident Population of NETs in the 7MM (2017-2028)
  • Table 6: Total Prevalent Cases of NETs in the United States (2017-2028)
  • Table 7: Total Incident Cases of NETs in the United States (2017-2028)
  • Table 8: Diagnosed prevalent cases of NETs in the United States (2017-2028)
  • Table 9: Symptom based classification of NETs in the United States (2017-2028)
  • Table 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028)
  • Table 11: Site-specific prevalent cases of NETs in the United States (2017-2028)
  • Table 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
  • Table 13: Stage-wise prevalent cases of NETs in the United States (2017-2028)
  • Table 14: Total Prevalent Cases of NETs in Germany (2017-2028)
  • Table 15: Total Incident Cases of NETs in Germany (2017-2028)
  • Table 16: Diagnosed prevalent cases of NETs in Germany (2017-2028)
  • Table 17: Symptom based classification of NETs in Germany (2017-2028)
  • Table 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028)
  • Table 19: Site-specific prevalent cases of NETs in Germany (2017-2028)
  • Table 20: Grade-wise prevalent cases of NETs in Germany (2017-2028)
  • Table 21: Stage-wise prevalent cases of NETs in Germany (2017-2028)
  • Table 22: Total Prevalent Cases of NETs in France (2017-2028)
  • Table 23: Total Incident Cases of NETs in France (2017-2028)
  • Table 24: Diagnosed prevalent cases of NETs in France (2017-2028)
  • Table 25: Symptom based classification of NETs in France (2017-2028)
  • Table 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028)
  • Table 27: Site-specific prevalent cases of NETs in France (2017-2028)
  • Table 28: Grade-wise prevalent cases of NETs in France (2017-2028)
  • Table 29: Stage-wise prevalent cases of NETs in France (2017-2028)
  • Table 30: Total Prevalent Cases of NETs in Italy (2017-2028)
  • Table 31: Total Incident Cases of NETs in Italy (2017-2028)
  • Table 32: Diagnosed prevalent cases of NETs in Italy (2017-2028)
  • Table 33: Symptom based classification of NETs in Italy (2017-2028)
  • Table 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028)
  • Table 35: Site-specific prevalent cases of NETs in Italy (2017-2028)
  • Table 36: Grade-wise prevalent cases of NETs in Italy (2017-2028)
  • Table 37: Stage-wise prevalent cases of NETs in Italy (2017-2028)
  • Table 38: Total Prevalent Cases of NETs in Spain (2017-2028)
  • Table 39: Total Incident Cases of NETs in Spain (2017-2028)
  • Table 40: Diagnosed prevalent cases of NETs in Spain (2017-2028)
  • Table 41: Symptom based classification of NETs in Spain (2017-2028)
  • Table 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028)
  • Table 43: Site-specific prevalent cases of NETs in Spain (2017-2028)
  • Table 44: Grade-wise prevalent cases of NETs in Spain (2017-2028)
  • Table 45: Stage-wise prevalent cases of NETs in Spain (2017-2028)
  • Table 46: Total Prevalent Cases of NETs in the UK (2017-2028)
  • Table 47: Total Incident Cases of NETs in the UK (2017-2028)
  • Table 48: Diagnosed prevalent cases of NETs in the UK (2017-2028)
  • Table 49: Symptom based classification of NETs in the UK (2017-2028)
  • Table 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028)
  • Table 51: Site-specific prevalent cases of NETs in the UK(2017-2028)
  • Table 52: Grade-wise prevalent cases of NETs in the UK (2017-2028)
  • Table 53: Stage-wise prevalent cases of NETs in the UK (2017-2028)
  • Table 54: Total Prevalent Cases of NETs in Japan (2017-2028)
  • Table 55: Total Incident Cases of NETs in Japan (2017-2028)
  • Table 56: Diagnosed prevalent cases of NETs in Japan (2017-2028)
  • Table 57: Symptom based classification of NETs in Japan (2017-2028)
  • Table 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028)
  • Table 59: Site-specific prevalent cases of NETs in Japan (2017-2028)
  • Table 60: Grade-wise prevalent cases of NETs in Japan (2017-2028)
  • Table 61: Stage-wise prevalent cases of NETs in Japan (2017-2028)

List of Figures

  • Figure 1: Classification of Neuroendocrine Tumors
  • Figure 2: Causes of Neuroendocrine Tumors
  • Figure 3: Targeting critical signaling pathways in NETs
  • Figure 4: Total Prevalent Population of NETs in the 7MM (2017-2028)
  • Figure 5: Total Incident Population of NETs in the 7MM (2017-2028)
  • Figure 6: Total Prevalent cases of NETs in the United States (2017-2028)
  • Figure 7: Total Incident cases of NETs in the United States (2017-2028)
  • Figure 8: Diagnosed prevalent cases of NETs in the United States (2017-2028)
  • Figure 9: Symptom based classification of NETs in the United States (2017-2028)
  • Figure 10: Diagnosed prevalent cases based on Malignancy in the United States (2017-2028)
  • Figure 11: Site-specific prevalent cases of NETs in the United States (2017-2028)
  • Figure 12: Grade-wise prevalent cases of NETs in the United States (2016-2027)
  • Figure 13: Stage-wise prevalent cases of NETs in the United States (2017-2028)
  • Figure 14: Total Prevalent cases of NETs in Germany (2017-2028)
  • Figure 15: Total Incident cases of NETs in Germany (2017-2028)
  • Figure 16: Diagnosed prevalent cases of NETs in Germany (2017-2028)
  • Figure 17: Symptom based classification of NETs in Germany (2017-2028)
  • Figure 18: Diagnosed prevalent cases based on Malignancy in Germany (2017-2028)
  • Figure 19: Site-specific prevalent cases of NETs in Germany (2017-2028)
  • Figure 20: Grade-wise prevalent cases of NETs in Germany (2017-2028)
  • Figure 21: Stage-wise prevalent cases of NETs in Germany (2017-2028)
  • Figure 22: Total Prevalent cases of NETs in the France (2017-2028)
  • Figure 23: Total Incident cases of NETs in the France (2017-2028)
  • Figure 24: Diagnosed prevalent cases of NETs in France (2017-2028)
  • Figure 25: Symptom based classification of NETs in France (2017-2028)
  • Figure 26: Diagnosed prevalent cases based on Malignancy in France (2017-2028)
  • Figure 27: Site-specific prevalent cases of NETs in France (2017-2028)
  • Figure 28: Grade-wise prevalent cases of NETs in France (2017-2028)
  • Figure 29: Stage-wise prevalent cases of NETs in France (2017-2028)
  • Figure 30: Total Prevalent cases of NETs in the Italy (2017-2028)
  • Figure 31: Total Incident cases of NETs in the Italy (2017-2028)
  • Figure 32: Diagnosed prevalent cases of NETs in Italy (2017-2028)
  • Figure 33: Symptom based classification of NETs in Italy (2017-2028)
  • Figure 34: Diagnosed prevalent cases based on Malignancy in Italy (2017-2028)
  • Figure 35: Site-specific prevalent cases of NETs in Italy (2017-2028)
  • Figure 36: Grade-wise prevalent cases of NETs in Italy (2017-2028)
  • Figure 37: Stage-wise prevalent cases of NETs in Italy (2017-2028)
  • Figure 38: Total Prevalent cases of NETs in the Spain (2017-2028)
  • Figure 39: Total Incident cases of NETs in the Spain (2017-2028)
  • Figure 40: Diagnosed prevalent cases of NETs in Spain (2017-2028)
  • Figure 41: Symptom based classification of NETs in Spain (2017-2028)
  • Figure 42: Diagnosed prevalent cases based on Malignancy in Spain (2017-2028)
  • Figure 43: Site-specific prevalent cases of NETs in Spain (2017-2028)
  • Figure 44: Grade-wise prevalent cases of NETs in Spain (2017-2028)
  • Figure 45: Stage-wise prevalent cases of NETs in Spain (2017-2028)
  • Figure 46: Total Prevalent cases of NETs in the UK (2017-2028)
  • Figure 47: Total Incident cases of NETs in the UK (2017-2028)
  • Figure 48: Diagnosed prevalent cases of NETs in the UK (2017-2028)
  • Figure 49: Symptom based classification of NETs in the UK (2017-2028)
  • Figure 50: Diagnosed prevalent cases based on Malignancy in the UK (2017-2028)
  • Figure 51: Site-specific prevalent cases of NETs in the UK (2017-2028)
  • Figure 52: Grade-wise prevalent cases of NETs in the UK (2017-2028)
  • Figure 53: Stage-wise prevalent cases of NETs in the UK (2017-2028)
  • Figure 54: Total Prevalent cases of NETs in Japan (2017-2028)
  • Figure 55: Total Incident cases of NETs in Japan (2017-2028)
  • Figure 56: Diagnosed prevalent cases of NETs in Japan (2017-2028)
  • Figure 57: Symptom based classification of NETs in the Japan (2017-2028)
  • Figure 58: Diagnosed prevalent cases based on Malignancy in Japan (2017-2028)
  • Figure 59: Site-specific prevalent cases of NETs in Japan (2017-2028)
  • Figure 60: Grade-wise prevalent cases of NETs in Japan (2017-2028)
  • Figure 61: Stage-wise prevalent cases of NETs in Japan (2017-2028)
  • Figure 62: Treatment of Neuroendocrine tumors
  • Figure 63: Unmet needs

DelveInsight's 'Neuroendocrine Tumors (NETs)- Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Neuroendocrine Tumors in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Neuroendocrine Tumors Disease Understanding

According to the Neuroendocrine Tumor Patient Foundation- "Neuroendocrine tumors (NETs) are a complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from cells called neuroendocrine cells. Like all cancers, NETs develop when the specialized cells undergo changes causing them to divide uncontrollably and grow into an abnormal tissue mass (tumor)".

Neuroendocrine Tumors Epidemiology

The Neuroendocrine Tumors (NETs) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Neuroendocrine Tumors are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Neuroendocrine Tumors Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases) scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Neuroendocrine Tumors (NETs) in 7 MM was found to be 453,191, in the year 2017.

Report Scope

  • The report covers detailed overview of Neuroendocrine Tumors explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Neuroendocrine Tumors in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases in 7MM

Key strengths

  • 10 Year Forecast of Neuroendocrine Tumors epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of NETs
  • Prevalent Cases according to segmentation: total prevalent population, total incident population, total diagnosed prevalent cases of Neuroendocrine Tumors, symptom based classification, diagnosed prevalent cased based on malignancy, site-specific prevalent cases, grade-specific prevalent cases and stage-specific prevalent cases

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Neuroendocrine Tumors Epidemiology Overview at a Glance

  • 2.1. Market (%) Distribution of Neuroendocrine Tumors in 2017
  • 2.2. Market (%) Distribution of Neuroendocrine Tumors in 2028

3. Disease Background and Overview: Neuroendocrine Tumors (NET)

  • 3.1. Introduction
  • 3.2. Classification of Neuroendocrine Tumors
  • 3.3. Causes
  • 3.4. Risk Factors
  • 3.5. Symptoms
  • 3.6. Pathophysiology
  • 3.7. Diagnosis
    • 3.7.1. Grading of NETs:
    • 3.7.2. Staging of NETs:

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Prevalent Patient Population of NETs
  • 4.3. Total Incident Patient Population of NETs

5. Country Wise-Epidemiology of NETs

  • 5.1. United States
    • 5.1.1. Total Prevalent Cases of NETs in the United States
    • 5.1.2. Total Incident Cases of NETs in the United States
    • 5.1.3. Diagnosed prevalent cases of NETs in the United States
    • 5.1.4. Symptom based classification of NETs
    • 5.1.5. Diagnosed prevalent cases based on Malignancy
    • 5.1.6. Site-specific prevalent cases of NETs
    • 5.1.7. Grade-wise prevalent cases of NETs
    • 5.1.8. Stage-wise prevalent cases of NETs
  • 5.2. EU5 Countries
  • 5.3. Germany
    • 5.3.1. Total Prevalent Cases of NETs in Germany
    • 5.3.2. Total Incident Cases of NETs in Germany
    • 5.3.3. Diagnosed prevalent cases of NETs in Germany
    • 5.3.4. Symptom based classification of NETs
    • 5.3.5. Diagnosed prevalent cases based on Malignancy
    • 5.3.6. Site-specific prevalent cases of NETs
    • 5.3.7. Grade-wise prevalent cases of NETs
    • 5.3.8. Stage-wise prevalent cases of NETs
  • 5.4. France
    • 5.4.1. Total Prevalent Cases of NETs in France
    • 5.4.2. Total Incident Cases of NETs in France
    • 5.4.3. Diagnosed prevalent cases of NETs in France
    • 5.4.4. Symptom based classification of NETs
    • 5.4.5. Diagnosed prevalent cases based on Malignancy
    • 5.4.6. Site-specific prevalent cases of NETs
    • 5.4.7. Grade-wise prevalent cases of NETs
    • 5.4.8. Stage-wise prevalent cases of NETs
  • 5.5. Italy
    • 5.5.1. Total Prevalent Cases of NETs in Italy
    • 5.5.2. Total Incident Cases of NETs in Italy
    • 5.5.3. Diagnosed prevalent cases of NETs in Italy
    • 5.5.4. Symptom based classification of NETs
    • 5.5.5. Diagnosed prevalent cases based on Malignancy
    • 5.5.6. Site-specific prevalent cases of NETs
    • 5.5.7. Grade-wise prevalent cases of NETs
    • 5.5.8. Stage-wise prevalent cases of NETs
  • 5.6. Spain
    • 5.6.1. Total Prevalent Cases of NETs in Spain
    • 5.6.2. Total Incident Cases of NETs in Spain
    • 5.6.3. Diagnosed prevalent cases of NETs in Spain
    • 5.6.4. Symptom based classification of NETs
    • 5.6.5. Diagnosed prevalent cases based on Malignancy
    • 5.6.6. Site-specific prevalent cases of NETs
    • 5.6.7. Grade-wise prevalent cases of NETs
    • 5.6.8. Stage-wise prevalent cases of NETs
  • 5.7. United Kingdom
    • 5.7.1. Total Prevalent Cases of NETs in the UK
    • 5.7.2. Total Incident Cases of NETs in the UK
    • 5.7.3. Diagnosed prevalent cases of NETs in the UK
    • 5.7.4. Symptom based classification of NETs
    • 5.7.5. Diagnosed prevalent cases based on Malignancy
    • 5.7.6. Site-specific prevalent cases of NETs
    • 5.7.7. Grade-wise prevalent cases of NETs
    • 5.7.8. Stage-wise prevalent cases of NETs
  • 5.8. Japan
    • 5.8.1. Total Prevalent Cases of NETs in Japan
    • 5.8.2. Total Incident Cases of NETs in Japan
    • 5.8.3. Diagnosed prevalent cases of NETs in Japan
    • 5.8.4. Symptom based classification of NETs
    • 5.8.5. Diagnosed prevalent cases based on Malignancy
    • 5.8.6. Site-specific prevalent cases of NETs
    • 5.8.7. Grade-wise prevalent cases of NETs
  • 5.9. Stage-wise prevalent cases of NETs

6. Treatment Algorithm

7. Unmet needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Back to Top
전화 문의
F A Q